77 research outputs found
Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384.
Stavudine (d4T) was, until recently, one of the most widely prescribed antiretroviral drugs worldwide. While there has been a major shift away from d4T use in resource-limited countries, a large number of patients have previously received (or continue to receive) d4T, and many have developed peripheral neuropathy. The identification of genetic predictors of increased risk might suggest novel therapeutic targets for such patients. In AIDS Clinical Trials Group protocol 384, antiretroviral-naïve patients were randomized to d4T/didanosine (ddI)- or zidovudine/lamivudine-containing regimens. Data from d4T/ddI recipients were analyzed for genome-wide associations (approximately 1 million genetic loci) with new onset distal sensory peripheral neuropathy. Analyses involved 254 patients (49 % White, 34 % Black, 17 % Hispanic), comprising 90 peripheral neuropathy cases (32 grade 1, 35 grade 2, 23 grade 3) and 164 controls. After correcting for multiple comparisons, no polymorphism was consistently associated with neuropathy among all patients, among White, Black, and Hispanic patients analyzed separately, both in genome-wide analyses (threshold, P < 5.0 × 10(-8)) and focused on 46 neuropathy-associated genes (threshold, P < 3.5 × 10(-5)). In the latter analyses, the lowest P values were in KIF1A among Whites (rs10199388, P = 8.4 × 10(-4)), in LITAF among Blacks (rs13333308, P = 6.0 × 10(-6)), and in NEFL among Hispanics (rs17763685, P = 5.6 × 10(-6)). Susceptibility to d4T/ddI-associated neuropathy is not explained by a single genetic variant with a marked effect
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
Background: Progressive multifocal leukoencephalopathy (PML) was reported to have developed in three patients treated with natalizumab. We conducted an evaluation to determine whether PML had developed in any other treated patients.
Methods: We invited patients who had participated in clinical trials in which they received recent or long-term treatment with natalizumab for multiple sclerosis, Crohn's disease, or rheumatoid arthritis to participate. The clinical history, physical examination, brain magnetic resonance imaging (MRI), and testing of cerebrospinal fluid for JC virus DNA were used by an expert panel to evaluate patients for PML. We estimated the risk of PML in patients who completed at least a clinical examination for PML or had an MRI.
Results: Of 3417 patients who had recently received natalizumab while participating in clinical trials, 3116 (91 percent) who were exposed to a mean of 17.9 monthly doses underwent evaluation for PML. Of these, 44 patients were referred to the expert panel because of clinical findings of possible PML, abnormalities on MRI, or a high plasma viral load of JC virus. No patient had detectable JC virus DNA in the cerebrospinal fluid. PML was ruled out in 43 of the 44 patients, but it could not be ruled out in one patient who had multiple sclerosis and progression of neurologic disease because data on cerebrospinal fluid testing and follow-up MRI were not available. Only the three previously reported cases of PML were confirmed (1.0 per 1000 treated patients; 95 percent confidence interval, 0.2 to 2.8 per 1000).
Conclusions: A detailed review of possible cases of PML in patients exposed to natalizumab found no new cases and suggested a risk of PML of roughly 1 in 1000 patients treated with natalizumab for a mean of 17.9 months. The risk associated with longer treatment is not known
Minimal muscle damage after a marathon and no influence of beetroot juice on inflammation and recovery
This study examined whether beetroot juice (BTJ) would attenuate inflammation and muscle
damage following a marathon. Using a double blind, independent group’s design, 34 runners
(~16 previous marathons completed) consumed either BTJ or an isocaloric placebo (PLA) for
3 days following a marathon. Maximal isometric voluntary contractions (MIVC),
countermovement jumps (CMJ), muscle soreness, serum cytokines, leucocytosis, creatine
kinase (CK), high sensitivity C-reactive protein (hs-CRP) and aspartate aminotransferase
(AST) were measured pre, post, and on the 2 days after the marathon. CMJ and MIVC were
reduced after the marathon (P0.05).
Muscle soreness was increased in the day after the marathon (BTJ; 45±48 vs. PLA; 46±39
mm) and had returned to baseline by day 2, irrespective of supplementation (P=0.694).
Cytokines (Interleukin-6; IL-6, interleukin-8, tumour necrosis factor-α) were increased
immediately post-marathon but apart from IL-6 had returned to baseline values by day 1 post.
No interaction effects were evident for IL-6 (P=0.213). Leucocytes increased 1.7 fold after
the race and remained elevated 2 days post, irrespective of supplement (P<0.0001). CK
peaked at 1 day post marathon (BTJ: 965±967 & PLA: 1141±979 IU·L-1) and like AST and
hs-CRP, was still elevated 2 days after the marathon (P<0.05); however, no group differences
were present for these variables. Beetroot juice did not attenuate inflammation or reduce
muscle damage following a marathon, possibly because most of these indices were not
markedly different from baseline values in the days after the marathon
Estruturas secretoras de mucilagem em Hibiscus pernambucensis Arruda (Malvaceae): distribuição, caracterização morfoanatômica e histoquímica
Factors Associated with Revision Surgery after Internal Fixation of Hip Fractures
Background: Femoral neck fractures are associated with high rates of revision surgery after management with internal fixation. Using data from the Fixation using Alternative Implants for the Treatment of Hip fractures (FAITH) trial evaluating methods of internal fixation in patients with femoral neck fractures, we investigated associations between baseline and surgical factors and the need for revision surgery to promote healing, relieve pain, treat infection or improve function over 24 months postsurgery. Additionally, we investigated factors associated with (1) hardware removal and (2) implant exchange from cancellous screws (CS) or sliding hip screw (SHS) to total hip arthroplasty, hemiarthroplasty, or another internal fixation device. Methods: We identified 15 potential factors a priori that may be associated with revision surgery, 7 with hardware removal, and 14 with implant exchange. We used multivariable Cox proportional hazards analyses in our investigation. Results: Factors associated with increased risk of revision surgery included: female sex, [hazard ratio (HR) 1.79, 95% confidence interval (CI) 1.25-2.50; P = 0.001], higher body mass index (fo
Improved Approximation Algorithms for Minimum-Space Advertisement Scheduling
We study a scheduling problem involving the optimal placement of advertisement images in a shared space over time. The problem is a generalization of the classical scheduling problem P jjCmax , and involves scheduling each job on a speci ed number of parallel machines (not necessarily simultaneously) with a goal of minimizing the makespan. In 1969 Graham showed that processing jobs in decreasing order of size, assigning each to the currently-least-loaded machine, yields a 4/3-approximation for P jjCmax . Our main result is a proof that the natural generalization of Graham's algorithm also yields a 4/3-approximation to the minimum-space advertisement scheduling problem. Previously, this algorithm was only known to give an approximation ratio of 2, and the best known approximation ratio for any algorithm for the minimum-space ad scheduling problem was 3/2. Our proof requires a number of new structural insights, which leads to a new lower bound for the problem and a non-trivial linear programming relaxation. We also provide a pseudo-polynomial approximation scheme for the problem (polynomial in the size of the problem and the number of machines)
- …